Erythropoietin in the treatment of iron overload in a patient with hemolytic anemia and pyruvate kinase deficiency.
Iron overload has been reported with pyruvate kinase deficiency. Erythropoietin (EPO) may lead to iron deficiency; thus, patients who are unable to be phlebotomized due to anemia may benefit from EPO as a treatment of iron overload.
Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, Tex., 78234-6200.
S J
SJ
Vukelja
D000328:Adult; D000743:Anemia, Hemolytic / Q000150:complications*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007501:Iron / Q000378:metabolism*; D011770:Pyruvate Kinase / Q000172:deficiency*
D004921:Erythropoietin; D007501:Iron; D011770:Pyruvate Kinase